Business UpdateJul 2, 2026, 04:01 AM
Oculis to Present Late-Stage Portfolio at Piper Sandler Conference
AI Summary
Oculis Holding AG announced that its management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference on July 10. The company will provide an overview and update on its innovative late-stage portfolio, highlighting Privosegtor, which received Breakthrough Therapy and PRIME designations for optic neuritis, targeting a $7B+ market, and Licaminlimab for dry eye disease. Oculis emphasized its strong balance sheet and advanced pipeline.
Key Highlights
- Oculis management to present at Piper Sandler Virtual Ophthalmology Conference on July 10.
- Sylvia Cheung, CFO, will participate in a fireside chat at 9:30 AM ET.
- Company will provide an overview and update on its late-stage portfolio.
- Privosegtor received Breakthrough Therapy (FDA) and PRIME (EMA) designations for optic neuritis.
- Privosegtor targets an estimated $7B+ market opportunity in the U.S. for optic neuropathies.
- Licaminlimab is being evaluated in the PREDICT-1 trial for dry eye disease (DED).
Price Impact
More from OCS